Effect of ivacaftor therapy on exhaled nitric oxide in patients with cystic fibrosis.

doi:10.1016/j.jcf.2015.07.001

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Effect of ivacaftor therapy on exhaled nitric oxide in patients with cystic fibrosis.

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society - 1 Nov 2015

Grasemann Hartmut, Gonska Tanja, Avolio Julie, Klingel Michelle, Tullis Elizabeth, Ratjen Felix

Abstract excerpt

UNLABELLED: Airways of patients with cystic fibrosis are deficient for nitric oxide. Low nitric oxide in cystic fibrosis has been shown to be associated with poor pulmonary function and risk of infection with certain pathogens. Treatment of cystic fibrosis patients with the cystic fibrosis transmembrane conductance regulator (CFTR)-targeting drug ivacaftor results in improved pulmonary function. The effect of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aminophenols
Share to Child
Share to Cystic Fibrosis
Share to Cystic Fibrosis Transmembrane Conductance Regulator

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Exhalation

Share to Nitric Oxide

Share to Quinolones

Share to Young Adult

Source

Open in PubMed

Identifiers

PMID: 26168933
DOI: 10.1016/j.jcf.2015.07.001

Genes

CFTR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.